The total return over the past 12 months is -6.80% vs. +16.94% for the S&P 500. So far it's up -21.43% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (6.87%) | (11.67%) | (48.22%) | (68.89%) | (61.43%) | N/A |
| Total Return CAGR | (6.80%) | (11.37%) | (48.14%) | (68.87%) | (61.41%) | N/A |
| Revenue CAGR | (13.27%) | (18.76%) | (2.59%) | +36.51% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aytu BioPharma, Inc. (AYTU)
| Year | Start price | End price | AYTU Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.60 | $2.04 | (21.43%) | +14.51% | (35.94%) |
| 2025 | $1.70 | $2.60 | +55.56% | +17.72% | +37.84% |
| 2024 | $2.84 | $1.70 | (40.79%) | +24.89% | (65.68%) |
| 2023 | $3.80 | $2.84 | (25.49%) | +26.19% | (51.68%) |
| 2022 | $27.00 | $3.80 | (85.87%) | (18.17%) | (67.70%) |
| 2021 | $119.60 | $27.00 | (77.43%) | +28.74% | (106.17%) |
| 2020 | $194.00 | $119.60 | (38.35%) | +18.37% | (56.72%) |
| 2019 | $158.00 | $194.00 | +22.79% | +31.22% | (8.43%) |
| 2018 | $8,920.00 | $158.00 | (98.23%) | (4.56%) | (93.67%) |
| 2017 | $96,000.00 | $8,920.00 | (90.71%) | +21.70% | (112.41%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
